TCR-alpha constant gene knockout was performed to reduce the risk of graft-versus-host-disease (GVHD), and CD52 knocked out to permit augmented lymphodepletion with ALLO627 (humanised anti-CD52 antibody) plus fludarabine and cyclophosphamide. This evidence concerns the gene CD52 and graft versus host disease.